Individual research recommendation details

Recommendation ID

MTG66/01

Question

Additional research could help address uncertainties in the evidence, although the case for cost savings remains unlikely.

Although the committee acknowledged that the Game et al. (2018) RCT was well conducted, it felt that additional research could help resolve some uncertainties around the cost and clinical case for 3C Patch. Specifically, research identifying the most appropriate stopping rule, and the associated clinical outcomes of implementing the rule, would help address key uncertainties within the cost case. Additional collection of resource use data on unhealed hard-to-heal ulcers could also reduce uncertainty in the cost case. Further to this, evidence could be collected on an UrgoStart-experienced population, as this would be reflective of current NHS care. Clinical experts thought a trial on this population would be feasible. The committee concluded that although further research could be done, on balance it was unlikely to result in a cost-saving case for 3C Patch based on the decision problem evaluated in this guidance

Any explanatory notes
(if applicable)

Source guidance details

Comes from guidance

3C Patch for treating diabetic foot ulcers

Number

MTG66

Date issued

March 2022

Other details